Objective: To evaluate the clinical efficacy of hybrid therapy for TASC C/D aortoiliac arteriosclerosis obliterans. Methods: The clinical data of 48 patients (66 limbs) with TASC C/D (including TASC C in 22 cases and TASC D in 26 cases) aortoiliac arteriosclerosis occlusive diseases undergoing hybrid revascularization procedures from May 2012 to May 2014 were analyzed. The perioperative conditions were evaluated, the revascularization results among patients with different Fontaine classifications were compared, and the influential factors for primary patency were analyzed. Results: The hybrid procedures were successfully performed in all 48 patients (66 limbs), and technical success rate was 100%. One patient underwent amputation on postoperative day 5 due to severe gangrene and infection of the lower limb, but no death occurred and the incidence of perioperative complications was 16.67%. The postoperative distance of intermittent claudication (568 m vs. 92 m) and ankle-brachial index (0.75 vs. 0.25) were significantly higher than those before operation (both P<0.05). The average period of follow-up was 24 months, the 6-month and 1- and 2-year primary patency rate was 95.45%, 90.91 % and 87.88%, and secondary patency rate was 98.48%, 96.97% and 92.42%, respectively. The primary patency rate in patients with Fontaine stage II and III were significantly higher than that in patients with Fontaine stage IV (P=0.036, 0.015), which however had no statistical difference between patients with Fontaine stage II and III (P>0.05). The presence of diabetes and dyslipidaemia were independent risk factors for decreased primary patency (P=0.026, 0.003). Conclusion: Hybrid therapy is a safe and effective treatment for TASC C/D aortoiliac arteriosclerosis obliterans.